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Summary
Background: Statins reduce the incidence of cardiovascular events in patients with
acute myocardial infarction (AMI). Although all statins are equally effective in sec-
ondary prevention, there might be certain differences in the effects of lipophilic and
hydrophilic statins. Therefore, our aim is to compare the effectiveness of lipophilic
atorvastatin and hydrophilic pravastatin in secondary prevention after AMI.
Methods and results: This study is a prospective, randomized, open-label, multi-
center study of 500 patients with AMI. Patients that have undergone successful
percutaneous coronary intervention will be randomly allocated to receive either
atorvastatin or pravastatin with the treatment goal of lowering their low-density
lipoprotein-cholesterol level below 100mg/dl for 2 years. The primary endpoint
will be death due to any cause, nonfatal MI, nonfatal stroke, unstable angina,
or congestive heart failure requiring hospital admission, or any type of coronary
revascularization.
Conclusion: This is the ﬁrst multicenter trial to compare the effects and safety of
lipophilic and hydrophilic statin therapy in Japanese patients with AMI. It addresses
an important issue and could inﬂuence the use of statin treatment in the secondary
prevention of coronary arte
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ardiovascular incidents are the second leading
ause of death in Japan. Many large-scale clinical
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fationale and design of assessment of lipophilic vs.
rials in Western countries have shown that statins
educe the incidence of cardiovascular events in
atients with acute myocardial infarction (AMI)
1]. Recently, several studies on the beneﬁcial
ffects of early statin therapy for Japanese patients
ith AMI have been reported [2,3]. The OACIS-
IPID study of Japanese patients with AMI revealed
hat early treatment with pravastatin reduces the
ecurrence of major adverse cardiac events; there
as a 44% relative reduction in the primary com-
ined endpoint of death, nonfatal MI, unstable
ngina, stroke, revascularization, and other car-
iovascular diseases [4]. In the MUSASHI-AMI study
f Japanese patients with AMI, a lipid-lowering
trategy with statins decreased subsequent car-
iovascular events, particularly, congestive heart
ailure and unstable angina [5]. In the ESTABLISH
tudy of Japanese patients with acute coronary
yndromes, early aggressive lipid-lowering ther-
py with atorvastatin for 6 months signiﬁcantly
ecreased the plaque volume in the coronary arter-
es, as measured by serial intravascular ultrasound
6].
Different statins are equally effective in sec-
ndary prevention after AMI. However, based on
tudies in which experimental animal models were
sed, it has been reported that each statin has
different effect depending on its water sol-
bility [7,8]. For example, in comparison with
ydrophilic pravastatin, lipophilic statins enhance
yocardial stunning in association with adenosine
riphosphate reduction after ischemia—reperfusion
njury in dogs. This suggests that hydrophilic statins
ight be more cardioprotective than lipophilic
tatins, particularly in patients undergoing reper-
usion therapy for AMI. Indeed, in a subanalysis
f the MUSASHI-AMI study, hydrophilic pravastatin
as found to be superior to lipophilic statins in
reventing new Q-wave appearance and reduc-
ng cardiovascular events [9]; however, this was
retrospective reanalysis of the MUSASHI-AMI
tudy in which patients were randomized to any
vailable statin or control (no statin) [5]. It has
een reported that clopidogrel is less effective
n inhibiting platelet aggregation when coadminis-
ered with atorvastatin, while its effectiveness was
ot altered by pravastatin. This is because ator-
astatin could competitively inhibit the activation
f hepatic CYP3A4, which metabolizes clopido-
rel to its pharmacologically active form [10]. On
he other hand, lipophilic statins may be superior
o hydrophilic statins in preventing cardiovascular
vents because of their potent pleiotropic effects
uch as the inhibition of pro-inﬂammatory cytokine
roduction or matrix metalloproteinase expression
11,12].
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The PROVE-I trial, which was a head-to-
ead comparison of lipid-lowering therapy with
torvastatin and pravastatin, showed that lipid
owering with lipophilic atorvastatin at 80mg/day
rovided greater protection against death and
ardiovascular events than lipid lowering with
ydrophilic pravastatin at 40mg/day in patients
ith acute coronary syndrome [13]; however, the
esults reﬂected the difference in the low-density
ipoprotein-cholesterol (LDL-C) levels achieved dur-
ng follow-up (95mg/dl vs. 62mg/dl) rather than
he difference in the water solubility of the statins.
n addition, the doses of statins used in this trial
xceeded the clinical doses administered in Japan.
herefore, prospective studies of lipophilic vs.
ydrophilic statins at their most clinically effec-
ive doses and at equal LDL-C levels are required
o identify differences between the cardioprotec-
ive effects of lipophilic and hydrophilic statins in
apanese patients with AMI.
To achieve equal LDL-C levels with both lipophilic
nd hydrophilic statins, we added ezetimibe to
he statin therapy when the target LDL-C level of
100mg/dl was not achieved. In comparison with
he use of statins alone, the combination of statins
nd ezetimibe inhibits both cholesterol synthesis
nd intestinal cholesterol absorption, resulting in
pproximately 20% greater reduction in the LDL-C
evel [14,15]. However, it is not known whether the
dditional LDL-C-lowering effect achieved by eze-
imibe addition to statin therapy will lead to clinical
eneﬁts.
ethods
bjective
he assessment of lipophilic vs. hydrophilic statin
herapy in acute myocardial infarction (ALPS-AMI)
tudy is a head-to-head comparison of the efﬁcacy
f lipophilic atorvastatin vs. hydrophilic pravastatin
t clinical doses in Japan in secondary prevention
fter AMI. Based on a retrospective reanalysis of
he MUSASHI-AMI study [9], we hypothesize that
ravastatin will reduce the incidence of the com-
osite endpoint of cardiovascular death, nonfatal
I, rehospitalization for unstable angina, coronary
evascularization, or stroke over at least 2 years of
ollow-up relative to atorvastatin therapy.tudy population
he ALPS-AMI study is a prospective, randomized,
pen-label, blinded endpoint study. In this trial,
e are enrolling men and women who have been
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lFigure 1 ALPS-AMI study design. AMI, acute myocardial
infarction; PCI, percutaneous coronary intervention; LDL-
C, low-density lipoprotein-cholesterol.
hospitalized for both ST-segment elevation and non-
ST-segment elevation MI. Patients with AMI who
satisfy all criteria for inclusion will be enrolled
within 96 h of receiving successful percutaneous
coronary intervention (PCI). Such patients will pro-
vide written informed consent and be randomly
allocated to receive 10mg of either atorvastatin or
pravastatin once daily (Fig. 1). Patients with prior
lipid-lowering therapy will also be randomized to
the atorvastatin or pravastatin groups. Their dose
will be increased to 20mg, and the treatment goal
is to reduce the LDL-C level below 100mg/dl. If the
subject’s LDL-C level is elevated, i.e., >100mg/dl
after 4 weeks of statin treatment, 10mg ezetim-
ibe will be added. Coronary angiography (CAG) will
be performed at baseline and at 6—9 months after
PCI. Safety monitoring includes blood tests for liver
function and creatine kinase (CK) (Fig. 2).
Major exclusion criteria include the presence
of hemodynamic events (hypotension, congestive
heart failure, acute mitral regurgitation, or acute
ventricular septal defect) and serious arrhythmic
Figure 2 Flowchart showing the study timeline. CAG,
coronary angiography; echo, echocardiography; ECG,
electrocardiography.
m
s
u
s
n
a
a
t
a
S
T
m
s
8
t
t
s
(
hY. Kashima et al.
vents. Patients in whom coronary artery bypass
rafting (CABG) is planned are excluded. Other
xclusion criteria include age <18 years, pregnancy,
ctive liver or renal disease, and subjects with LDL-
levels <70mg/dl without statin therapy.
Participants will be recruited at 20 participating
ites in Nagano and Niigata Prefectures of Japan.
he protocol has been reviewed and approved by
ach participating site’s ethics committee, and
ritten informed consent will be obtained. Dur-
ng follow-up, no speciﬁc recommendations are
ade with respect to the diagnostic and ther-
peutic strategy, with the exception that other
ipid-lowering drugs should not be administered
fter randomization until day 28. All management
ecisions are left to the discretion of each patient’s
reating physician. Study medication is discontin-
ed when there are concerns for the patient’s
afety such as the development of hepatic dysfunc-
ion or myopathy.
Patients were enrolled from July 2008, and
nrollment will continue until June 2010. The study
as been registered at the University Hospital Med-
cal Information Network (UMIN) (ID 000001521).
tudy endpoints
he primary endpoint is the occurrence of one of
he following: death due to any cause, nonfatal
I, nonfatal stroke, unstable angina or conges-
ive heart failure requiring hospital admission, or
ny type of coronary revascularization occurring at
east 28 days after randomization.
The secondary endpoints include changes in the
inimal lumen diameter (MLD) and % stenosis at the
ite of PCI, changes in left ventricular function eval-
ated by echocardiography, changes in the levels of
erum high-sensitivity C-reactive protein and brain
atriuretic peptide, the percentage of patients who
chieve the target LDL-C level of <100mg/dl, and
ny adverse incidents including changes in labora-
ory values such as those in the liver function tests
nd CK levels.
ample size
he trial has been designed based on the infor-
ation available up until Spring 2008. An initial
ample size of 500 patients was selected to afford
0% power to detect a relative risk reduction in
he primary endpoint by a two-sided two-sample
-test at a signiﬁcance level of 0.05. The sample
ize was based on anticipated event rates at 1 year
9.9% in the lipophilic statin group and 3.6% in the
ydrophilic statin group) [9].
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[ationale and design of assessment of lipophilic vs.
onclusion
he ALPS-AMI trial is the ﬁrst multicenter trial
o compare the effects and safety of lipophilic
torvastatin and hydrophilic pravastatin therapy in
apanese patients with AMI. This study addresses
he important issue of the performance of lipophilic
s. hydrophilic statins in secondary prevention after
MI. It could inﬂuence the treatment of many hun-
reds of thousands of patients.
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